TrialStudy of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Trial details
- Registry ID
- NCT05317819
- Phase
- Phase 3
Drug research
ADI-PEG20
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Pegargiminase; pegargiminase
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular CarcinomaNCT05317819 | Polaris Group | Phase 3 | Recruiting | 2028-09Estimated |
| Study of ADI-PEG 20 Versus Placebo in Subjects With NASHNCT05842512 | Polaris Group | Phase 2 | Recruiting | 2027-12-31Estimated |
Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
Trial details
- Registry ID
- NCT05842512
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |